Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 8/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | NLRP3 | Q96P20 | 6/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | IL1B | P01584 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29326172 | 0.91 | SYK (0.39) | SYKHDAC4HDAC6NLRP3KCNH2 | |
| SCHEMBL29326120 | 0.89 | NLRP3 (0.50) | SYKHDAC4HDAC6NLRP3KCNH2 | |
| SCHEMBL29326168 | 0.87 | IL1B (0.44) | SYKHDAC4HDAC6NLRP3KCNH2 | |
| SCHEMBL26434277 | 0.80 | NLRP3 (0.51) | NLRP3KCNH2IL1BGAAKMT2A | |
| SCHEMBL29326482 | 0.80 | NLRP3 (0.51) | NLRP3KCNH2IL1BGAAKMT2A | |
| SCHEMBL29326836 | 0.79 | SYK (0.41) | SYKNLRP3KCNH2 | |
| SCHEMBL29326016 | 0.77 | HDAC4 (0.41) | SYKHDAC4HDAC6GAA | |
| SCHEMBL27182195 | 0.77 | NLRP3 (0.55) | NLRP3KCNH2IL1BHCRTR1 | |
| SCHEMBL29326846 | 0.76 | NLRP3 (0.54) | NLRP3KCNH2IL1BHCRTR1 | |
| SCHEMBL29326550 | 0.72 | PGR (0.38) | NLRP3KCNH2IL1BGAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NICO THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NLRP3, NLRP1, PYCARD | SYK 813/4885HDAC4 411/4885HDAC6 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.